m6A修饰在乳腺癌中的分子机制研究进展
Progress in Molecular Mechanism of RNA N6-Methyladenosine Modification in Breast Cancer
DOI: 10.12677/ACM.2022.125555, PDF,   
作者: 郑仁靖*, 喻远航, 邓惠芳, 吕莲秋, 王 涵, 张 波#：华中科技大学同济医学院附属协和医院乳腺甲状腺外科，湖北 武汉
关键词: 乳腺癌；N6-甲基腺苷修饰；靶向治疗；Breast Cancer； N6-Methyladenosine Modification； Targeted Therapy
摘要: RNA的N6-甲基腺苷(m6A)修饰是参与肿瘤恶性进程的最广泛的表观遗传修饰。大量研究表明，m6A甲基化与乳腺癌的增殖、侵袭、转移和发展密切相关。近年来，随着m6A修饰及其相关调控蛋白在乳腺癌中的生物学功能和特异性分子机制研究的不断深入，两者之间复杂的调控关系逐渐清晰。本文旨在探讨近年来m6A修饰在肿瘤学中的研究进展。此外，我们试图探讨m6A修饰的新型小分子药物在乳腺癌治疗中的前景和局限性。
Abstract: N6-methyladenosine RNA (m6A) is mRNA’s most abundant and extensive epigenetic modification involved in the malignant process of tumors. It is widely reported that m6A is involved in mammary carcinogenesis, invasion, metastasis and development. Recently, as the studies of m6A are getting further, the complex modulation network between breast cancer and m6A is getting clearer. This review aims to elaborate current status and perspectives of m6A study in oncology. In addition, we discuss the application prospects and limitations of small-molecule drugs targeting m6A in breast cancer.
文章引用：郑仁靖, 喻远航, 邓惠芳, 吕莲秋, 王涵, 张波. m6A修饰在乳腺癌中的分子机制研究进展[J]. 临床医学进展, 2022, 12(5): 3844-3849. https://doi.org/10.12677/ACM.2022.125555

参考文献

[1] Roundtree, I.A., Evans, M.E., Pan, T. and He, C. (2017) Dynamic RNA Modifications in Gene Expression Regulation. Cell, 169, 1187-1200. [Google Scholar] [CrossRef] [PubMed]
[2] Shi, H., Wei, J. and He, C. (2019) Where, When, and How: Context-Dependent Functions of RNA Methylation Writers, Readers, and Erasers. Molecular Cell, 74, 640-650. [Google Scholar] [CrossRef] [PubMed]
[3] Zhou, J., Wan, J., Gao, X., Zhang, X., Jaffrey, S.R. and Qian, S.-B. (2015) Dynamic m6A mRNA methylation directs translational control of heat shock response. Nature, 526, 591-594. [Google Scholar] [CrossRef] [PubMed]
[4] Cai, X., Wang, X., Cao, C., Gao, Y., Zhang, S., Yang, Z., et al. (2018) HBXIP-Elevated Methyltransferase METTL3 Promotes the Progression of Breast Cancer via Inhibiting Tumor Suppressor Let-7g. Cancer Letters, 415, 11-19. [Google Scholar] [CrossRef] [PubMed]
[5] Liu, Y., Wang, R., Zhang, L., Li, J., Lou, K. and Shi, B. (2017) The Lipid Metabolism Gene FTO Influences Breast Cancer Cell Energy Metabolism via the PI3K/AKT Signaling Path-way. Oncology Letters, 13, 4685-4690. [Google Scholar] [CrossRef] [PubMed]
[6] Niu, Y., Lin, Z., Wan, A., Chen, H., Liang, H., Sun, L., Wang, Y., et al. (2019) RNA N6-Methyladenosine Demethylase FTO Promotes Breast Tumor Progression through Inhibiting BNIP3. Molecular Cancer, 18, Article No. 46. [Google Scholar] [CrossRef] [PubMed]
[7] Song, Y., Zheng, C., Tao, Y., Huang, R. and Zhang, Q. (2021) N6-Methyladenosine Regulators Are Involved in the Progression of and Have Clinical Impact on Breast Cancer. Medical science Monitor, 27, Article ID: e929615. [Google Scholar] [CrossRef] 
[8] Wang, H., Xu, B. and Shi, J. (2020) N6-Methyladenosine METTL3 Promotes the Breast Cancer Progression via Targeting Bcl-2, Gene, 722, Article ID: 144076. [Google Scholar] [CrossRef] [PubMed]
[9] Wei, M., Bai, J.W., Niu, L., Zhang, Y.Q., Chen, H.Y. and Zhang, G.J. (2020) The Complex Roles and Therapeutic Implications of m6A Modifications in Breast Cancer. Frontiers in Cell and Developmental Biology, 8, Article ID: 615071. [Google Scholar] [CrossRef] [PubMed]
[10] Wu, L., Wu, D., Ning, J., Liu, W. and Zhang, D. (2019) Changes of N6-Methyladenosine Modulators Promote Breast Cancer Progression. BMC Cancer, 19, Article No. 326. [Google Scholar] [CrossRef] [PubMed]
[11] Wu, Y., Wang, Z., Han, L., Guo, Z., Yan, B., Guo, L., et al. (2022) PRMT5 Regulates RNA m6A Demethylation for Doxorubicin Sensitivity in Breast cancer. Molecular Therapy. [Google Scholar] [CrossRef] [PubMed]
[12] Xiong, J., He, J., Zhu, J., Pan, J., Liao, W., Ye, H., et al. (2022) Lactylation-Driven METTL3-Mediated RNA m6A Modification Promotes Immunosuppression of Tumor-Infiltrating Myeloid Cells. Molecular Cell. [Google Scholar] [CrossRef] [PubMed]
[13] Yue, L., Li, L., Liu, F., Hu, N., Zhang, W., Bai, X., et al. (2013) The Oncoprotein HBXIP Activates Transcriptional Coregulatory Protein LMO4 via Sp1 to Promote Proliferation of Breast Cancer Cells. Carcinogenesis, 34, 927-935. [Google Scholar] [CrossRef] [PubMed]
[14] Zhang, C., Samanta, D., Lu, H., Bullen, J.W., Zhang, H., Chen, I., et al. (2016) Hypoxia Induces the Breast Cancer Stem Cell Phenotype by HIF-Dependent and ALKBH5-Mediated m6A-Demethylation of NANOG mRNA. Proceedings of the National Academy of Sciences of the United States of America, 113, E2047-E2056. [Google Scholar] [CrossRef] [PubMed]
[15] Fu, Y., Dominissini, D., Rechavi, G. and He, C. (2014) Gene Ex-pression Regulation Mediated through Reversible m6A RNA Methylation. Nature Reviews Genetics, 15, 293-306. [Google Scholar] [CrossRef] [PubMed]
[16] He, C. (2010) Grand Challenge Commentary: RNA Epigenetics? Nature Chemical Biology, 6, 863-865. [Google Scholar] [CrossRef] [PubMed]
[17] Deng, X., Su, R., Feng, X., Wei, M. and Chen, J. (2018) Role of N6-Methyladenosine Modification in Cancer. Current Opinion in Genetics & Development, 48, 1-7. [Google Scholar] [CrossRef] [PubMed]
[18] Deng, X., Su, R., Weng, H., Huang, H., Li, Z. and Chen, J. (2018) RNA N6-Methyladenosine Modification in Cancers: Current Status and Perspectives. Cell Research, 28, 507-517. [Google Scholar] [CrossRef] [PubMed]
[19] Esteve-Puig, R., Bueno-Costa, A. and Esteller, M. (2020) Writers, Readers and Erasers of RNA Modifications in Cancer. Cancer Letters, 474, 127-137. [Google Scholar] [CrossRef] [PubMed]
[20] Panneerdoss, S., Eedunuri, V.K., Yadav, P., Timilsina, S., Raja-manickam, S., et al. (2018) Cross-Talk among Writers, Readers, and Erasers of m6A Regulates Cancer Growth and Pro-gression. Science Advances, 4, Article No. eaar8263. [Google Scholar] [CrossRef] [PubMed]
[21] Chai, R., Chang, Y., Chang, X., Pang, B., An, S., Zhang, K., et al. (2021) YTHDF2 Facilitates UBXN1 mRNA Decay by Recognizing METTL3-Mediated m6A Modification to Activate NF-κB and Promote the Malignant Progression of Glioma. Journal of Hematology & Oncology, 14, Article No. 109. [Google Scholar] [CrossRef] [PubMed]
[22] Liu, J., Yue, Y., Han, D., Wang, X., Fu, Y., Zhang, L., et al. (2014) A METTL3-METTL14 Complex Mediates Mammalian Nuclear RNA N6-Adenosine Methylation. Nature Chemical Biology, 10, 93-95. [Google Scholar] [CrossRef] [PubMed]
[23] Wang, S., Zou, X., Chen, Y., Cho, W.C. and Zhou, X. (2020) Effect of N6-Methyladenosine Regulators on Progression and Prognosis of Triple-Negative Breast Cancer. Frontiers in Genet-ics, 11, Article ID: 580036. [Google Scholar] [CrossRef] [PubMed]
[24] Huang, T., Cao, L., Feng, N., Xu, B., Dong, Y. and Wang, M. (2021) N6-Methyladenosine (m6A)-Mediated lncRNA DLGAP1-AS1enhances Breast Canceradriamycin Resistance through miR-299-3p/WTAP Feedback Loop. Bioengineered, 12, 10935-10944. [Google Scholar] [CrossRef] [PubMed]
[25] Wang, X., Zhao, B.S., Roundtree, I.A., Lu, Z., Han, D., Ma, H., et al. (2015) N6-Methyladenosine Modulates Messenger RNA Translation Efficiency, Cell, 161, 1388-1399. [Google Scholar] [CrossRef] [PubMed]
[26] Petri, B.J., Piell, K.M., South Whitt, G.C., Wilt, A.E., Poulton, C.C., Lehman, N.L., et al. (2021) HNRNPA2B1 Regulates Tamoxifen- and Fulvestrant-Sensitivity and Hallmarks of Endo-crine Resistance in Breast Cancer Cells. Cancer Letters, 518, 152-168. [Google Scholar] [CrossRef] [PubMed]
[27] Su, R., Dong, L., Li, C., Nachtergaele, S., Wunderlich, M., Qing, Y., et al. (2018) R-2HG Exhibits Anti-Tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling. Cell, 172, 90-105.e123. [Google Scholar] [CrossRef] [PubMed]
[28] Chen, B., Ye, F., Yu, L., Jia, G., Huang, X., Zhang, X., et al. (2012) Development of Cell-Active N6-Methyladenosine RNA Demethylase FTO Inhibitor. Journal of the American Chemical Society, 134, 17963-17971. [Google Scholar] [CrossRef] [PubMed]
[29] Yankova, E., Blackaby, W., Albertella, M., Rak, J., De Braekeleer, E., Tsagkogeorga, G., et al. (2021) Small-Molecule Inhibition of METTL3 as a Strategy against Myeloid Leukaemia. Nature, 593, 597-601. [Google Scholar] [CrossRef] [PubMed]

为你推荐